You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,485,462


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,485,462
Title:Commercially viable process for in-vitro mass culture of Chlorophytum borivilianum
Abstract: The present invention relates to the commercially viable process for in-vitro mass culture of Chlorophytum borivilianum. The present invention process for in-vitro mass culture of Chlorophytum borivilianum is simple, faster and suitable for production of disease free root tubers of uniform quality. The process of the present invention for in-vitro mass culture of Chlorophytum borivilianum employs media with low concentration of nutrients and phytohormones.
Inventor(s): Neera; Bhardwaj (Gujarat, IN), Murali; K. S. (Maharashtra, IN)
Assignee: Reliance Life Sciences Pvt. Ltd. (Rabale, Navi Mumbai, Maharashtra, IN)
Application Number:11/095,161
Patent Claims:1. A commercially viable process for in-vitro mass culture of Chlorophytum borivilianum of true to type clone comprising the steps of: a. isolating meristematic explants from selected parts of a mother plant; b. cleaning the explants by washing thoroughly under running water to remove soil adhering to the explants, cutting approximately 1 to 2 cm pieces of root top with crown meristem, cleaning with a mild detergent of about 0.5 to 5% Tween-20 solution with intermittent shaking for a period of 15 to 30 minutes, and then washing thoroughly with demineralized water; c. subjecting the explants to a primary sterilization by treating the explants with a solution containing a fungicide comprising Bavistin at a concentration of 0.05% to 0.2% and a bactericide including streptomycin at a concentration of 0.1% to 1% for a period of 20-80 minutes, and then rinsing with sterile water; d. subjecting the primary sterilized explants to a secondary sterilization by cutting the crown part of tuberous roots about 0.5-1 cm below the apex in a Laminar flow bench, treating with a surface sterilizing agent comprising sodium hypochlorite in a range of 0.5-2% for a period of 0.05-0.25% for a period of 2 to 5 minutes, then rinsing with sterile distilled water thrice; e. preparing an explant that is a meristematic tissue for inoculation, by trimming the explant to about 0.3 to 0.6 cm cube, without damaging the crown meristem, and isolating the meristematic tissue; f. inoculating the explants on a culture initiation medium comprising basal salts of MS medium to give multiple shoots; g. transferring the cultures to a proliferation and elongation medium; and, h. transferring the elongated shoots to a rooting medium comprising basal salts of MS medium to produce said in vitro culture of Chlorophytum borivilianum of true to type clone.

2. The process as claimed in claim 1, wherein the MS medium used for culture initiation is of half strength.

3. The process as claimed in claim 1, wherein the culture initiation medium is a hormone free medium.

4. The process as claimed in claim 1, wherein the proliferation and elongation medium is supplemented with a low concentration of a phytohormone.

5. The process as claimed in claim 1, including phytohormone in the range of about 0.01 to about 0.9%.

6. The process as claimed in claim 1, wherein the MS medium used for rooting medium is of half strength.

7. The process as claimed in claim 1, wherein rooting medium is a hormone free medium.

8. The process as claimed in claim 4, wherein the phytohormone is 6-benzyl amino purine in the range of 0.05% to 0.5%.

9. The process as claimed in claim 1, wherein the proliferation and elongation medium is basal salts of MS medium.

10. The process as claimed in claim 1, wherein the fungicide is selected from the group consisting of Bavistin, Captan, Dithane, Thiram, and Thiovit.

11. The process as claimed in claim 1, wherein the bactericide is selected from the group consisting of streptomycin, chloramphenicol, ciprofloxacin, cefotaume, kanamycin and carbenicillin.

12. The process as claimed in claim 1, wherein the surface sterilizing agent is selected from the group consisting of sodium hypochlorite and calcium hypochlorite in a concentration between 0.2% to 2.0%.

13. The process as claimed in claim 1, including phytohormone selected from the group consisting of natural and synthetic auxins, cytohinins, Gibberellin and cytokinin-active urea derivatives.

14. The process as claimed in claim 1, including natural and synthetic cytokinins selected from the group consisting of 6-aminopurin (adenine), 6-aminopurine hydrochloride, 6-aminopurine hemisulfate, benzylaminopurine (BAP), kinetin, zeating and n.sup 6-substituted derivatives.

15. The process as claimed in claim 4, wherein the phytohormone is 6-benzyl amino purine in the range of about 0.01 to about 0.9%.

16. A commercially viable process for in-vitro mass culture of Chlorophytum borivilianum of true to type clone comprising the steps of: a. isolating meristematic explants from leaf, lateral roots, or crown meristem of a mother plant; b. cleaning the explants by washing through under running water to removal soil adhering to the explants, cutting approximately to 1 to 2 cm pieces of root top, cleaning with a 0.5 to 5% Tween-20 solution with intermittent shaking for a period 15 to 30 minutes, then washing thoroughly with demineralized water; c. subjecting the explants to primary sterilization by treating the explants with a solution containing 0.05% to 0.2% Bavistin and 0.1% to 1% of streptomycin for 20-80 minutes, then rinsing with sterile water; d. subjecting the primary sterilized explants to secondary sterilization by cutting the crown part of tuberous roots about 0.5-1 cm below the apex in a Laminar flow bench, treating with 0.5-2% of sodium hypochlorite for a period of 5 to 20 minutes, then rinsing with autoclaved distilled water repeatedly, treating with 0.05-0.25% of mercuric chloride for 2 to 5 minutes, then rinsing with sterile distilled water thrice; e. preparing the explant that is meristematic tissue for inoculation, by trimming the explant to a cube of about 0.3 to 0.6 cm, without damaging the crown meristem, and taking care of isolating the meristematic tissue; f. inoculating the explants with a medium of basal salts to produce multiple shoots; g. transferring the cultures to a medium of basal salts of MS medium to produce a proliferation and elongation medium; and h. transferring the elongated shoots to a medium of basal salts of MS medium to provide for a rooting medium.

17. The process as claimed in claim 16, wherein crown meristem is the preferred explant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.